Key result
Novel NSAIDs containing an N-acyl hydrazone subunit protected against thromboembolic events in mice, with survival rates up to 40% compared to 30% for acetylsalicylic acid.
Why the study?
Do novel NSAIDs containing an N-acyl hydrazone subunit improve antiplatelet and antithrombotic activities compared to ASA in preclinical models?
Population
In vitro platelet models and in vivo mouse models
Comparison
Novel nonsteroidal anti-inflammatory drugs 1-5… vs Acetylsalicylic acid (ASA)
Design
Preclinical
Authors
Loading...
Requires human trials before any clinical consideration; leaves open whether these compounds improve antithrombotic outcomes versus ASA.
Do novel NSAIDs containing an N-acyl hydrazone subunit improve antiplatelet and antithrombotic activities compared to ASA in preclinical models?
Absolute Event Rate: 40% vs 30%
Novel NSAIDs containing an N-acyl hydrazone subunit demonstrated promising antiplatelet and antithrombotic activities with potentially shorter bleeding times compared to ASA in preclinical models.
Chelucci et al. (2014) studied this question. NSAIDs containing an N-acyl hydrazone subunit (Compounds 1-5) vs. Acetylsalicylic acid (ASA) was evaluated on Thromboembolic event survival rate. Novel NSAIDs containing an N-acyl hydrazone subunit protected against thromboembolic events in mice, with survival rates up to 40% compared to 30% for acetylsalicylic acid.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: